The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: Major depression summary.
depression
guideline
mood disorders
treatment
Journal
Bipolar disorders
ISSN: 1399-5618
Titre abrégé: Bipolar Disord
Pays: Denmark
ID NLM: 100883596
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
pubmed:
16
12
2020
medline:
2
2
2021
entrez:
15
12
2020
Statut:
ppublish
Résumé
To provide a succinct, clinically useful summary of the management of major depression, based on the 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders (MDcpg To develop the MDcpg The depression summary provides a systematic approach to diagnosis, and a logical clinical framework for management. The latter begins with Actions, which include important strategies that should be implemented from the outset. These include lifestyle changes, psychoeducation and psychological interventions. The summary advocates the use of antidepressants in the management of depression as Choices and nominates seven medications that can be trialled as clinically indicated before moving to Alternatives for managing depression. Subsequent strategies regarding Medication include Increasing Dose, Augmenting and Switching (MIDAS). The summary also recommends the use of electroconvulsive therapy (ECT), and discusses how to approach non-response. The major depression summary provides up to date guidance regarding the management of major depressive disorder, as set out in the MDcpg
Substances chimiques
Antidepressive Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
788-804Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Malhi GS, Bell E, Bassett D, et al. The Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2021;55(1):7-117.
Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087-1206.
National Health and Medical Research Council. NHMRC additional levels of evidence and grades for recommendations for developers of guidelines. NHMRC. 2009.
Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9(1):90.
Heim C, Binder EB. Current research trends in early life stress and depression: review of human studies on sensitive periods, gene-environment interactions, and epigenetics. Exp Neurol. 2012;233(1):102-111.
WHO. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization; 2017.
Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34(1):119-138.
Moffitt TE, Caspi A, Taylor A, et al. How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment. Psychol Med. 2010;40(6):899-909.
Hirschfeld RMA. The epidemiology of depression and the evolution of treatment. J Clin Psychiatry. 2012;73(suppl. 1):5-9.
Kuehner C. Why is depression more common among women than among men? The Lancet Psychiatry. 2017;4(2):146-158.
Malhi GS, Irwin L, Hamilton A, et al. Modelling mood disorders: an ACE solution? Bipolar Disord. 2018;20(S2):4-16.
Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. JAMA Psychiatry. 1992;49(10):809-816.
Angst J, Gamma A, Rössler W, Ajdacic V, Klein DN. Long-term depression versus episodic major depression: results from the prospective Zurich study of a community sample. J Affect Disord. 2009;115(1-2):112-121.
Boschloo L, Schoevers RA, Beekman ATF, Smit JH, Van Hemert AM, Penninx BWJH. The four-year course of major depressive disorder: the role of staging and risk factor determination. Psychother Psychosom. 2014;83(5):279-288.
World Health Organization. The Global Burden of Disease: 2004 Update. 2008.
Malhi GS, Mann JJ. Depression. The Lancet. 2018;392(10161):2299-2312.
Stahl EA, Breen G, Forstner AJ, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet. 2019;51(5):793-803.
Cascading effects of stressors and inflammatory immune system activation: Implications for major depressive disorder [press release]. Canada: Canadian Medical Association; 2009.
Mistry S, Harrison JR, Smith DJ, Escott-Price V, Zammit S. The use of polygenic risk scores to identify phenotypes associated with genetic risk of schizophrenia: systematic review. Schizophr Res. 2018;197:2-8.
Murray G. Circadian science and psychiatry: of planets, proteins and persons. Aust N Z J Psychiatry. 2019;53(7):597-601.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5, 5th edn. Arlington, VA: American Psychiatric Publishing; 2013.
World Health Organization. International statistical classification of diseases and related health problems (11th Revision). Geneva: World Health Organisation; 2018.
Malhi GS, Bell E, Boyce P, Mulder R, Porter RJ. Unifying the diagnosis of mood disorders. Aust N Z J Psychiatry. 2020;54(6):561-565.
Malhi GS, Fritz K, Elangovan P, Irwin L. Mixed states: modelling and management. CNS Drugs. 2019;33(4):301-313.
Malhi GS, Bell E. Detecting classical bipolar disorder: a classic mistake? Bipolar Disord. 2019;21(8):679-683.
Malhi GS, Das P, Bell E, Mattingly G, Mannie Z. Modelling resilience in adolescence and adversity: a novel framework to inform research and practice. Transl Psychiat. 2019;9(1):316.
Cuijpers P. Four decades of outcome research on psychotherapies for adult depression: an overview of a series of meta-analyses. Canadian Psychology. 2017;58(1):7-19.
Cuijpers P, Noma H, Karyotaki E, Vinkers CH, Cipriani A, Furukawa TA. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry. 2020;19(1):92-107.
Patterson B, Boyle MH, Kivlenieks M, Van Ameringen M. The use of waitlists as control conditions in anxiety disorders research. J Psychiatr Res. 2016;83:112-120.
Lilienfeld SO, Ritschel LA, Lynn SJ, Cautin RL, Latzman RD. Why many clinical psychologists are resistant to evidence-based practice: Root causes and constructive remedies. Clinical Psychology Review. 2013;33(7):883-900.
Boschloo L, Bekhuis E, Weitz ES, et al. The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis. World Psychiatry. 2019;18(2):183-191.
Cuijpers P, Weitz E, Karyotaki E, Garber J, Andersson G. The effects of psychological treatment of maternal depression on children and parental functioning: a meta-analysis. Eur Child Adolesc Psychiatry. 2015;24(2):237-245.
Malhi GS, Tanious M. Optimal frequency of lithium administration in the treatment of bipolar disorder. CNS Drugs. 2011;25(4):289-298.
Nolen WA, Licht RW, Young AH, et al. What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium. Bipolar Disord. 2019;21(5):394-409.
Malhi GS, Gershon S, Outhred T. Lithiumeter: version 2.0. Bipolar Disord. 2016;18(8):631-641.
Lenze EJ, Mulsant BH, Blumberger DM, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. The Lancet. 2015;386(10011):2404-2412.
Bassett D, Parker G, Hamilton A, et al. Treatment-resistant depressive disorders: the when, how and what of augmentation therapy. Aust N Z J Psychiatry. 2019;53(3):187-189.
Mulder R, Hamilton A, Irwin L, et al. Treating depression with adjunctive antipsychotics. Bipolar Disord. 2018;20(suppl 2):17-24.
Taylor RW, Marwood L, Oprea E, et al. Pharmacological augmentation in unipolar depression: a guide to the guidelines. Int J Neuropsychopharmacol. 2020;23(9):587-625.
Boyce P, Hopwood M, Morris G, et al. Switching antidepressants in the treatment of major depression: when, how and what to switch to? J Affect Disord. 2020;261:160-163.
Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
Harris MG, Kazdin AE, Chiu WT, et al. Findings from world mental health surveys of the perceived helpfulness of treatment for patients with major depressive disorder. JAMA Psychiatry. 2020;77(8):830-841.
Semkovska M, Landau S, Dunne R, et al. Bitemporal versus high-dose unilateral twice-weekly electroconvulsive therapy for depression (EFFECT-Dep): a pragmatic, randomized, non-inferiority trial. Am J Psychiatry. 2016;173(4):408-417.
UK Ect Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet (London, England). 2003;361(9360):799-808.
Luchini F, Medda P, Mariani MG, Mauri M, Toni C, Perugi G. Electroconvulsive therapy in catatonic patients: efficacy and predictors of response. World J Psychiatry. 2015;5(2):182-192.
Dessens FM, van Paassen J, van Westerloo DJ, van der Wee NJ, van Vliet IM, van Noorden MS. Electroconvulsive therapy in the intensive care unit for the treatment of catatonia: a case series and review of the literature. Gen Hosp Psychiatry. 2016;38:37-41.
Weiss A, Hussain S, Ng B, et al. Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the administration of electroconvulsive therapy. Aust N Z J Psychiatry. 2019;53(7):609-623.
Ward HB, Fromson JA, Cooper JJ, De Oliveira G, Almeida M. Recommendations for the use of ECT in pregnancy: literature review and proposed clinical protocol. Arch Womens Ment Health. 2018;21(6):715-722.
Henssler J, Kurschus M, Franklin J, Bschor T, Baethge C. Long-term acute-phase treatment with antidepressants, 8 weeks and beyond: a systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2017;79(1):60-68.
Kato M, Hori H, Inoue T, et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. 2020.
Sim K, Lau WK, Sim J, Sum MY, Baldessarini RJ. Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials. Int J Neuropsychopharmacol. 2015;19(2).
Zhang Z, Zhang L, Zhang G, Jin J, Zheng Z. The effect of CBT and its modifications for relapse prevention in major depressive disorder: a systematic review and meta-analysis. BMC Psychiatry. 2018;18(1):50.
Karyotaki E, Smit Y, Holdt Henningsen K, et al. Combining pharmacotherapy and psychotherapy or monotherapy for major depression? A meta-analysis on the long-term effects. J Affect Disord. 2016;194:144-152.
Dodd S, Mitchell PB, Bauer M, et al. Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: an international consensus statement. World J Biol Psychiatry. 2018;19(5):330-348.
Carvajal C. Poor response to treatment: beyond medication. Dialogues Clin Neurosci. 2004;6(1):93-103.
McNaughton EC, Curran C, Granskie J, et al. Patient attitudes toward and goals for MDD treatment: a survey study. Patient Prefer Adherence. 2019;13:959-967.